David M. Reese - Feb 19, 2025 Form 4 Insider Report for AMGEN INC (AMGN)

Role
EVP & Chief Technology Officer
Signature
/s/ David M. Reese
Stock symbol
AMGN
Transactions as of
Feb 19, 2025
Transactions value $
-$8,871,783
Form type
4
Date filed
2/21/2025, 08:06 PM
Previous filing
May 9, 2024
Next filing
Mar 5, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMGN Common Stock Options Exercise $1.36M +8.71K +14.02% $156.35 70.9K Feb 19, 2025 Direct F1
transaction AMGN Common Stock Sale -$2.55M -8.71K -12.29% $293.22 62.1K Feb 19, 2025 Direct F2
transaction AMGN Common Stock Sale -$7.68M -25.2K -40.59% $304.44 36.9K Feb 21, 2025 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMGN Nqso (Right to Buy) Options Exercise $0 -8.71K -100% $0.00 0 Feb 19, 2025 Common Stock 8.71K $156.35 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired in connection with the exercise of stock options expiring on May 3, 2026.
F2 The price reported is an average price. The prices ranged from $291.90 to $295.97 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.
F3 The price reported is an average price. The prices ranged from $297.19 to $305.33 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.
F4 These shares include 707 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.